top of page
  • Writer's pictureFutureMeds

FutureMeds Appoints Nachiket Chandak as Senior Director of Business Development

Nach Chandak, a distinguished sales professional with over 16 years of experience in the pharmaceutical and healthcare industry, has joined FutureMeds as our new Senior Director of Business Development. Nach will be working closely with Cameron Glen, the VP of Global Business Development, to solidify and enhance client relationships and partnerships.

After becoming the 1st European DCT Site Network, our organisation recently launched FutureMeds @home, a DCT solution that aims to speed up DCT adoption across the continent. Joining FutureMeds, Nach is set to bolster the rapid expansion of the network by forging stronger ties with clients.

His role as the Senior Director of Business Development will encompass building and maintaining relationships with key stakeholders, partners, and clients, identifying new market opportunities, potential partnerships, and areas for expansion.

“At FutureMeds, my priority for the BD team is to foster growth for our clients, strengthen collaboration across internal departments, and cultivate symbiotic relationships with partner companies, leading to mutual growth and success. I am confident that Nach’s vast experience, impressive track record, and dynamic skill set will be invaluable assets to all of us.”

- Cameron Glen, VP of Business Development at FutureMeds

Throughout his career, Nach has held various sales positions, consistently contributing to revenue growth for prominent organisations that shape the industry.

Nach started his clinical trial journey at Datamonitor Healthcare in 2007, where he gained insight into clinical development, financing of biotechs and due diligence of products. Due to his passion to contribute to the development of new medicines for patients, he joined PPD, where he excelled in securing new projects for the central laboratory business and forging multi-year partnerships with prominent pharmaceutical companies.

After 4 years at PPD, he joined ICON Plc as Director of Business Development, helped the organisation build closer ties with Sponsors, and primarily sold phase II-III clinical research services.

In 2017, he joined Parexel, where he played a crucial role in driving new business and establishing long-term partnerships with pharmaceutical companies.

“My CRO experience working with major pharmaceutical & biotech companies gives me a holistic perspective on overall trial delivery and how we can increase trial efficiency and enrol patients for our clients to bring new medicines to market.”

- Nachiket Chandak, Senior Director of Business Development at FutureMeds

Nach's academic background is as impressive as his professional one. After earning a pharmacy degree and completing a Master's program in Drug Delivery from the School of Pharmacy in London, he pursued a Postgraduate Diploma in Business Administration to expand his knowledge of business administration.

Going Forwards

Nach’s short-term goal is to immerse himself in the business. Once aligned with FutureMeds’ goals and mission, he will be focusing on developing lasting partnerships with FutureMeds' pharma, biotech, and CRO clients.

“With my sales experience, I plan to build new client relationships and transform our existing ones into strategic partnerships. We have an excellent team at Futuremeds with a sound track record, and I am looking forward to contributing to our company’s growth.”

- Nachiket Chandak, Senior Director of Business Development at FutureMeds

About FutureMeds

FutureMeds is the 1st European Independent Dedicated DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 18 countries.

FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.

Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.

Follow us on LinkedIn

Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Commenting has been turned off.
bottom of page